Inhibition of cardiovascular cell proliferation by angiotensin receptor blockers: Are all molecules the same?

Journal of Hypertension

Volumn 26, Issue 5, 2008, Pages 973-980

  Benson, Stephen C ^a   Iguchi, Rumiko ^a   Ho, Christopher I ^b   Yamamoto, Koichi ^b   Kurtz, Theodore W ^b  

^a CALIFORNIA STATE UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Angiotensin; Angiotensin II type 1 receptor blockers; Cardiac fibroblast; Cardiovascular diseases; Cell proliferation; Cyclin D1; Growth factor; Hypertension; Platelet derived growth factor; Vascular smooth muscle

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; CYCLIN D1; EPROSARTAN; INSULIN; IRBESARTAN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLATELET DERIVED GROWTH FACTOR; TELMISARTAN;

ANIMAL CELL; ARTICLE; CELL PROLIFERATION; CHO CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; FIBROBLAST; HUMAN CELL CULTURE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; RAT; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE;

EID: 42049108222     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e3282f56ba5     Document Type: Article

References (20)

1. Mehta PK, Griendling KK. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol 2007; 292:C82-C97.
2. Asmar R. Targeting effective blood pressure control with angiotensin receptor blockers. Int J Clin Pract 2006; 60:315-320.
3. Cai X. Regulation of smooth muscle cells in development and vascular disease: current therapeutic strategies. Expert Rev Cardiovasc Ther 2006; 4:789-800.
4. Brown RD, Ambler SK, Mitchell MD, Long CS. The cardiac fibroblast: therapeutic target in myocardial remodeling and failure. Annu Rev Pharmacol Toxicol 2005; 45:657-687.
5. Martin MM, Willardson BM, Burton GF, White CR, McLaughlin JN, Bray SM, et al. Human angiotensin II Type 1 receptor isoforms encoded by messenger RNA splice variants are functionally distinct. Mol Endocrinol 2001; 15:281-293.
6. Chen K, Chen J, Li D, Zhang X, Mehta J. Angiotensin II regulation of collagen Type I expression in cardiac fibroblasts. Modulation by PPAR-γ ligand pioglitazone. Hypertension 2004; 44:655-661.
7. Baker KM, Kumar R. Intracellular angiotensin II induces cell proliferation independent of AT1 receptor. Am J Physiol Cell Physiol 2006; 291:C995-C1001.
8. Weber H, Taylor DS, Molloy CJ. Angiotensin II induces delayed mitogenesis and cellular proliferation in rat aortic smooth muscle cells. Correlation with the expression of specific endogenous growth factors and reversal by suramin. J Clin Invest 1994; 93:788-798.
9. Herbert JM, Delisee C, Dol F, Schaeffer P, Cazaubon C, Nisato D, Chatelain P. Effect of SR 47436, a novel angiotensin II AT1 receptor antagonist, on human vascular smooth muscle cells in vitro. Eur J Pharmacol 1994; 251:143-150.
10. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARg-modulating activity. Hypertension 2004; 43:993-1002.
11. Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 2004; 109:2054-2057.
12. Hsueh WA, Jackson S, Law RE. Control of vascular cell proliferation and migration by PPAR-gamma: a new approach to the macrovascular complications of diabetes. Diabetes Care 2001; 24:392-397.
13. Theocharis S, Margeli A, Vielh P, Kouraklis G. Peroxisome proliferator-activated receptor ligands as cell cycle modulators. Cancer Treat Rev 2004; 30:545-554.
14. Bruemmer D, Berger JP, Liu J, Kintscher U, Wakino S, Fleck E, et al. A nonthiazolidinedione partial peroxisome proliferator-activated receptor gamma ligand inhibits vascular smooth muscle cell growth. Eur J Pharmacol 2003; 466:225-234.
15. Palakurthi SS, Aktas H, Grubissich LM, Mortensen RM, Halperin JA. Anticancer effects of thiazolidinediones are independent of peroxisome proliferator activated receptor gamma and mediated by inhibition of translation initiation. Cancer Res 2001; 61:6213-6218.
16. Sherr CJ. Cancer cell cycles. Science 1966; 274:1672-1677.
17. Silverstein RL, Ram CV. Angiotensin-receptor blockers: benefits beyond lowering blood pressure. Cleve Clin J Med 2005; 72:825-832.
18. Kim S, Iwao H. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev 2002; 52:12-34.
19. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitial fibrosis and renin-angiotensin aldosterone system. Circulation 1991; 83:1849-1865.
20. Wagner J, Drab M, Bohlender J, Amann K, Wienen W, Ganten D. Effects of AT1 receptor blockade on blood pressure and the renin-angiotensin system in spontaneously hypertensive rats of the stroke prone strain. Clin Exp Hypertens 1998; 20:205-221.